Neogen reported quarterly earnings of $0.08 per share, beating consensus estimates of $0.05 and marking a 60% earnings surprise. The company also exceeded revenue expectations with $222.8 million, up from $209.19 million year-over-year. Despite strong performance, Neogen's Medical-Products industry ranks in the bottom 35% of Zacks industries. The stock has gained 86.1% year-to-date and holds a Zacks Rank #2 (Buy) rating.

The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.

Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.

The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.

The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.

The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.

The global Therapeutic Drug Monitoring (TDM) consumables market is projected to grow from USD 364.27 million in 2026 to USD 586.85 million by 2032, driven by an 8.22% CAGR. Growth is fueled by AI-enabled automation, integrated lab workflows, standardized collection devices, and improved specimen integrity. Key drivers include workflow integration, digital connectivity, and responsible AI governance across diverse regional markets with distinct operational priorities.

Bio-Rad Laboratories (BIO) shows modest growth in Clinical Diagnostics with quality controls and blood typing leading, supported by strong international presence. However, China weakness, geopolitical volatility, and foreign exchange headwinds constrain full-year outlook. The company maintains a Hold rating with reaffirmed guidance of 3% decline to 0.5% growth for 2026.

The global metabolomics market is projected to grow from USD 2.81 billion in 2025 to USD 9.01 billion by 2035, expanding at a CAGR of 12.36%. Growth is driven by precision medicine, biomarker discovery, and multiomics adoption, with oncology accounting for over 44% of the market. However, Q1 2026 faced challenges from geopolitical tensions, supply chain disruptions, and elevated logistics costs affecting laboratory budgets and procurement timelines.

The global magnetic bead purification kits market reached $4.08 billion in 2025 with an 11.6% CAGR and is projected to grow to $6.73 billion by 2030 (10.5% CAGR) and $10.42 billion by 2035 (9.1% CAGR). Growth is driven by expanding genomics research, molecular diagnostics, and high-throughput screening. Semi-automated kits dominate at 51.8% market share, while Asia-Pacific is the fastest-growing region at 12% CAGR. Key challenges include skilled labor shortages and automation infrastructure dependencies.

The global epigenetics market is estimated at USD 2.70 billion in 2025 and projected to reach USD 8.30 billion by 2034, expanding at a CAGR of 13.3%. Growth is driven by rising cancer burden, precision medicine adoption, liquid-biopsy development, and advances in sequencing technologies. DNA methylation dominates the technology segment at 48% market share, while kits and reagents lead products at 41%. Oncology represents the largest application at 60%, with pharmaceutical and biotech companies as the primary end-users at 44% market share. North America leads with 43% global revenue, while Asia-Pacific is the fastest-growing region.